Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice

Gold nanoparticles (AuNPs) decorated with antigens have recently emerged as promising tools for vaccine development due to their innate ability to provide stability to antigens and modulate immune responses. In this study, we have engineered deactivated virus-like particles (VLPs) by precisely funct...

Descripción completa

Detalles Bibliográficos
Autores: Salazar, Vivian A., Comenge, Joan, Suárez-López, Rosa, Burger, Judith A., Sanders, Rogier W., Bastús, Neus G., Jaime, Carlos, Joseph-Munne, Joan, Puntes, Víctor F.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/365146
Acceso en línea:http://hdl.handle.net/10261/365146
Access Level:acceso abierto
Palabra clave:Virus-like particles (VLPs)
Gold nanoparticles
Spike protein SARS-CoV-2
SARS-CoV-2 vaccine
id ES_d8feb43d42aaa805400ad09ef2b397df
oai_identifier_str oai:digital.csic.es:10261/365146
network_acronym_str ES
network_name_str España
repository_id_str
spelling Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c miceSalazar, Vivian A.Comenge, JoanSuárez-López, RosaBurger, Judith A.Sanders, Rogier W.Bastús, Neus G.Jaime, CarlosJoseph-Munne, JoanPuntes, Víctor F.Virus-like particles (VLPs)Gold nanoparticlesSpike protein SARS-CoV-2SARS-CoV-2 vaccineGold nanoparticles (AuNPs) decorated with antigens have recently emerged as promising tools for vaccine development due to their innate ability to provide stability to antigens and modulate immune responses. In this study, we have engineered deactivated virus-like particles (VLPs) by precisely functionalizing gold cores with coronas comprising the full SARS-CoV-2 spike protein (S). Using BALB/c mice as a model, we investigated the immunogenicity of these S-AuNPs-VLPs. Our results demonstrate that S-AuNPs-VLPs consistently enhanced antigen-specific antibody responses compared to the S protein free in solution. This enhancement included higher binding antibody titers, higher neutralizing capacity of antibodies, and stronger T-cell responses. Compared to the mRNA COVID-19 vaccine, where the S protein is synthesized in situ, S-AuNPs-VLPs induced comparable binding and neutralizing antibody responses, but substantially superior T-cell responses. In conclusion, our study highlights the potential of conjugated AuNPs as an effective antigendelivery system for protein-based vaccines targeting a broad spectrum of infectious diseases and other emergent virusesN.G.B. and V.P. acknowledge financial support from proyectos de I+D+i de programación conjunta internacional MCIN/AEI (CONCORD, PCI2019-103436) co-funded by the European Union, and Generalitat de Catalunya (2021-SGR-00878). ICN2 is supported by the Severo Ochoa program from Spanish MINECO (SEV-2017-0706) and is funded by the CERCA Programme/Generalitat de CatalunyaPeer reviewedMultidisciplinary Digital Publishing InstituteMinisterio de Ciencia e Innovación (España)Agencia Estatal de Investigación (España)European CommissionGeneralitat de CatalunyaMinisterio de Economía y Empresa (España)Ministerio de Ciencia, Innovación y Universidades (España)Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2024202420242024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/365146reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PCI2019-103436info:eu-repo/grantAgreement/AEI//SEV-2017-0706The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.3390/vaccines12080829https://doi.org/10.3390/vaccines12080829Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3651462026-05-22T06:33:51Z
dc.title.none.fl_str_mv Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
title Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
spellingShingle Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
Salazar, Vivian A.
Virus-like particles (VLPs)
Gold nanoparticles
Spike protein SARS-CoV-2
SARS-CoV-2 vaccine
title_short Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
title_full Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
title_fullStr Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
title_full_unstemmed Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
title_sort Gold nanoparticle virus-like particles presenting SARS-CoV-2 spike protein: Synthesis, biophysical properties and immunogenicity in BALB/c mice
dc.creator.none.fl_str_mv Salazar, Vivian A.
Comenge, Joan
Suárez-López, Rosa
Burger, Judith A.
Sanders, Rogier W.
Bastús, Neus G.
Jaime, Carlos
Joseph-Munne, Joan
Puntes, Víctor F.
author Salazar, Vivian A.
author_facet Salazar, Vivian A.
Comenge, Joan
Suárez-López, Rosa
Burger, Judith A.
Sanders, Rogier W.
Bastús, Neus G.
Jaime, Carlos
Joseph-Munne, Joan
Puntes, Víctor F.
author_role author
author2 Comenge, Joan
Suárez-López, Rosa
Burger, Judith A.
Sanders, Rogier W.
Bastús, Neus G.
Jaime, Carlos
Joseph-Munne, Joan
Puntes, Víctor F.
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia e Innovación (España)
Agencia Estatal de Investigación (España)
European Commission
Generalitat de Catalunya
Ministerio de Economía y Empresa (España)
Ministerio de Ciencia, Innovación y Universidades (España)
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Virus-like particles (VLPs)
Gold nanoparticles
Spike protein SARS-CoV-2
SARS-CoV-2 vaccine
topic Virus-like particles (VLPs)
Gold nanoparticles
Spike protein SARS-CoV-2
SARS-CoV-2 vaccine
description Gold nanoparticles (AuNPs) decorated with antigens have recently emerged as promising tools for vaccine development due to their innate ability to provide stability to antigens and modulate immune responses. In this study, we have engineered deactivated virus-like particles (VLPs) by precisely functionalizing gold cores with coronas comprising the full SARS-CoV-2 spike protein (S). Using BALB/c mice as a model, we investigated the immunogenicity of these S-AuNPs-VLPs. Our results demonstrate that S-AuNPs-VLPs consistently enhanced antigen-specific antibody responses compared to the S protein free in solution. This enhancement included higher binding antibody titers, higher neutralizing capacity of antibodies, and stronger T-cell responses. Compared to the mRNA COVID-19 vaccine, where the S protein is synthesized in situ, S-AuNPs-VLPs induced comparable binding and neutralizing antibody responses, but substantially superior T-cell responses. In conclusion, our study highlights the potential of conjugated AuNPs as an effective antigendelivery system for protein-based vaccines targeting a broad spectrum of infectious diseases and other emergent viruses
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/365146
url http://hdl.handle.net/10261/365146
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PCI2019-103436
info:eu-repo/grantAgreement/AEI//SEV-2017-0706
The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.3390/vaccines12080829
https://doi.org/10.3390/vaccines12080829
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421250768535552
score 15.811543

Similares en LA Referencia